Midi’s progesterone page identifies micronized powder inside an oral capsule and provides an inactive-ingredient list. It also calls the treatment compounded. Those details allow a more precise review than a general promise of hormone care, provided the ingredient, capsule shell and regulatory status are not collapsed into one claim.
Reviewed September 29, 2026, this assessment reads that product description alongside Midi’s care and pricing information. It distinguishes the documented formula from properties that would require a selected prescription or physical product. No medicine was purchased, inspected or tested, and no personal allergy assessment was performed.
Read this article by section
The powder is one component of the finished preparation
Midi’s product description names micronized progesterone powder as the active ingredient. It separately lists microcrystalline cellulose and a vegetarian capsule made with hypromellose and water. This is useful product-level information, but it remains the provider’s description rather than an assay of a delivered medicine.
The word micronized describes an aspect of the active ingredient; it is not another name for the shell or all the ingredients together. Our micronized meaning guide keeps those levels separate. Identifying the powder does not establish the manufacturing details, batch contents or suitability of the preparation for someone whose full clinical and allergy history has not been assessed.
The compounding statement controls the approval interpretation
The Midi page explicitly directs patients to ask about its compounded hormone therapy. FDA’s explanation says compounded drugs do not undergo its premarket approval for safety, effectiveness and quality. The appearance of an ingredient also used in approved medicines does not change that regulatory distinction.
The approval terminology guide therefore treats bioidentical and approved as different descriptions. Alloy’s review considers a pill promoted with an FDA-approved claim but without a complete supplied-product identity. The comparison establishes different public records; it cannot decide which preparation is appropriate for an individual or use a chemical resemblance as a substitute for finished-product approval.
Vegan and peanut-free wording has a defined source
Midi advertises the capsule as vegan and peanut free. Its stated inactive ingredients help explain the claim, but this review does not independently authenticate sourcing, contamination controls or an individual prescription. The language is attributed to Midi, not converted into allergy clearance.
For contrast, the Prometrium label declares peanut oil and gelatin for that specific product. It would be inaccurate to paste those ingredients onto Midi’s compound simply because both contain progesterone. It would be equally inaccurate to apply Midi’s ingredient description to every generic capsule. A meaningful ingredient comparison needs both exact records and a professional who can address the reader’s particular concern.
Oral form and another product’s indication are separate facts
Midi identifies oral micronized progesterone, while also publishing broad claims about bleeding, sleep, mood and uterine protection. Those claims do not make the product identical to every other oral progesterone preparation or establish all of the same studied uses.
The Prometrium label contains a defined endometrial-hyperplasia prevention indication for specified postmenopausal women receiving conjugated estrogen tablets. That belongs to the named approved product and its labeled setting. The route guide likewise does not authorize using an oral capsule by another route. A clinician needs to explain the evidence and purpose of the selected preparation rather than borrow a complete label from an ingredient match.
The listed supply has a separate clinical charge
The product offer starts at $35 for a thirty-day supply and describes out-of-pocket purchase. This is not the entire cost of beginning care. Midi’s pricing page lists a $250 self-pay initial visit of thirty minutes and a $150 return visit of fifteen minutes.
Actual insurance benefits and additional services are separate questions. The page says Medicare is out of network, describes a self-pay route for beneficiaries without submission of related claims, and says Medicaid and Medi-Cal patients are not accepted. These are the provider’s stated access conditions, not a general rule about all private care. A selected product, encounter and financial arrangement were not tested.
Delivery language does not remove location or clinical limits
The product page excludes Arizona from its availability statement. Door delivery therefore should not be read as unrestricted access throughout the country. Its clinician assessment also remains a condition of prescribing, rather than a promise that requesting the capsule will produce an order.
The broader hormone-care service describes treatment options, but that does not establish the renewal, cancellation or refund outcome for a selected compounded prescription. Evernow’s review examines a different situation where the care pathway is clearer than the actual formulation. Both require the reader to distinguish the clinical service being offered from the medicine and supply ultimately agreed.
A detailed description still leaves questions for the actual supply
Midi’s formula page gives a stronger starting point for ingredient questions than a bare hormone name. Its limits should remain just as visible: the record does not constitute testing of a batch, verification of a dispensing label or evidence that the product will deliver the advertised benefit to a particular patient.
The practical next discussion concerns what is prescribed, who compounds or dispenses it, which complete information accompanies it and how the clinician explains the intended use. FDA’s compounding resource supplies the regulatory context without rating the provider. This review documents the oral compounded option while leaving product authentication and personal clinical decisions to the professionals involved in care.
Documents behind the details
Read the source for the product, use and context it actually describes. A source type is not a rating of a provider.
- Midi Health: compounded oral micronized progesteroneProvider exact product description with active and inactive ingredients; vegan and peanut-free wording attributed, not independent allergy clearance or FDA approval · Checked 2026-09-29
- FDA: Understanding the Risks of Compounded DrugsFederal regulatory explanation; compounded preparations are not FDA-approved, no inference about inspection or quality of a named pharmacy · Checked 2026-09-29
- DailyMed: Prometrium progesterone capsule label, updated July 23, 2026Official structured label for the named oral product; chemical identity, micronization, formulation-specific ingredients and indications, not evidence of a reviewed provider supplying it · Checked 2026-09-29
- Midi: pricing and insuranceProvider consultation units and self-pay prices; plan-dependent insurance and separate out-of-pocket medicine, no selected benefit verification · Checked 2026-09-29
- Midi: hormone replacement therapyProvider care and access restrictions, including Medicaid/Medi-Cal and Medicare self-pay conditions; distinct from separate compounded capsule offer · Checked 2026-09-29